HOME >> BIOLOGY >> NEWS
Screening programs find health problems among former Hanford workers

A press conference to outline the results of medical screenings of former Hanford workers will be held at 11 a.m. PST on Tuesday, Nov. 2, in the Columbia Room of the Richland Red Lion (formerly the DoubleTree).

The conference is sponsored by the University of Washington, The Coalition to Protect Workers' Rights, and the Department of Energy.

The conference will include representatives of those groups, plus former workers who will be available for interviews. Media unable to attend the conference can obtain information about the results, after the briefing, by calling the number above.

The two projects involved have screened about 600 workers so far, with plans to screen an additional 20,000 for health problems related to their work at the Hanford nuclear site in southeastern Washington state. These evaluations are the most extensive of former Hanford workers to date.

Undiagnosed lung disease and hearing loss are the most common ailments noted thus far.

The conference comes at the beginning of the third annual "Health of the Hanford Site" conference sponsored by the University of Washington. The data on former workers will be presented in full along with other topics related to human and ecological health at Hanford. The conference gives scientists, contractors, workers, residents, tribal representatives and others an opportunity to exchange information and discuss past, present and future research regarding the site.

Members of the media are welcome to cover some or all of the conference, also held at the Red Lion. For more information, call the number above or visit the conference Web site at http://depts.washington.edu/cresp2/hos. Besides worker health, other topics at the conference will include contaminated high-level waste tanks, beryllium exposure and evaluation of human and ecological health risks.

Among the scheduled topics:

    - The two new studies that quantify the number of health problems that have affected
    '"/>


Contact: Walter Neary
wneary@u.washington.edu
206-543-3620
University of Washington
26-Oct-1999


Page: 1 2

Related biology news :

1. Society for Biomolecular Screening to hold ninth annual conference
2. Screening technique streamlines search for anticancer drugs
3. Screening certain infants can be lifesaving, Wake Forest study shows
4. Screening embryos for problem chromosomes
5. American Red Cross Launches New Genetic Screening Technology To Directly Detect Viruses
6. H Pylori Screening To Reduce The Risk Of Gastric Cancer
7. Vibrating Cells Could Be The Ultimate In Noninvasive Screening
8. Screening In Women Army Recruits Shows High Chlamydia Infection Rates
9. Researchers Develop Fast Screening Method For Water Testing
10. Genetic Screening May Be Tool For Selecting Cancer Treatment, Research Suggests
11. Cancer Test May Offer High-Risk Groups Quick, Affordable Screening For Tumors

Post Your Comments:
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: